Famciclovir
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Famciclovir: From Herpes Zoster and Genital Herpes to Post-Infectious Neuralgia
One-Sentence Summary
Famciclovir is an oral antiviral (a prodrug of penciclovir) used against herpesvirus infections such as shingles. The TxGNN model predicts it may be relevant to post-infectious neuralgia (pain that persists after shingles). Evidence is thin: 2 registered trials were retrieved, but neither tests famciclovir, and no publications were found for this indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA record; famciclovir is generally used for herpes zoster and genital herpes |
| Predicted New Indication | Post-infectious neuralgia |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L4 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the pack. Based on known pharmacology, famciclovir is converted to penciclovir, whose active form inhibits varicella-zoster virus (VZV) DNA polymerase. It can shorten the acute shingles episode.
Post-infectious (postherpetic) neuralgia is the most common complication of shingles. The link is therefore preventive: treating the acute viral phase may lower the risk of later nerve pain.
Famciclovir is not a neuropathic pain agent. It has no demonstrated effect on established neuralgia. Any benefit would be limited to preventing the condition, not treating it.
Clinical Trial Evidence
Both registered trials study acute herpes zoster pain. Neither tests famciclovir as the intervention, so they support the disease context only.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06798662 | Not applicable | Not yet recruiting | 120 | Nerve block (liposomal bupivacaine or ropivacaine) plus pulse radiofrequency for acute zoster pain; famciclovir is at most background antiviral therapy |
| NCT03120962 | Not applicable | Unknown | 140 | Early oxycodone in acute herpes zoster to prevent postherpetic neuralgia; famciclovir is not the intervention |
No SANCTR or PACTR identifiers were found.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 45/20.2.8/1157 | Macleods Famciclovir Tablets 125 mg | Film-coated tablet | Not stated in the registration record |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but no trial or publication tests famciclovir for post-infectious neuralgia. The mechanism supports prevention only, through treating acute zoster. This is a research question, not a treatment candidate.
Other predicted indications in this pack look stronger. Chickenpox reaches L2, with a completed Phase 3 paediatric PK/safety study (NCT00098046) and a completed Phase 3 randomised efficacy trial in herpes zoster (NCT01327144). Those studies do not show efficacy in chickenpox itself.
To proceed, the following is needed:
- SAHPRA package insert warnings and contraindications (blocking for safety screening)
- Mechanism of action data from DrugBank
- Trials or studies that test whether early famciclovir reduces postherpetic neuralgia incidence
- The approved indication text for the registered South African product
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.